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A crucial limitation to our understanding of Alzheimer’s disease has been the inability to test hypotheses on
live, patient-specific neurons. A recent study in Nature by Israel et al. (2012) reports that iPSC-derived
neurons from AD patients recapitulate multiple aspects of disease pathology.Alzheimer’s disease (AD) is the most
common form of age-related dementia,
characterized by progressive memory
loss and cognitive disturbance. Two path-
ological hallmarks are thought to be
crucial in the disease: (1) amyloid plaques,
primarily composed of the amyloid-
b protein (Ab), liberated from the amyloid
precursor protein (APP) via serial
cleavage by b- and g-secretase, and (2)
neurofibrillary tangles, composed of fila-
mentous accumulations of aggregated
hyperphosphorylated tau (reviewed in
Tanzi and Bertram, 2005).
Familial, early-onset (<60 years), auto-
somal-dominant forms of AD (FAD) can
be caused by fully penetrant mutations
in the genes APP, presenilin 1 (PSEN1),
and presenilin 2 (PSEN2). Sporadic AD
(sAD) is the more common form of the
disease, and usually involves late onset
owing to multifactorial genetic and envi-
ronmental risk factors (reviewed in Ber-
tram et al., 2010). In a large twin study,
the contribution of heritability to sAD
was estimated to be as high as 80%
(Gatz et al., 2006). The best-established
genetic risk factor is the ε4 allele of the
gene encoding apolipoprotein E (APOE)
(reviewed in Tanzi and Bertram, 2005).
Although postmortem studies have
provided a wealth of knowledge on the
pathological hallmarks of AD, post-
mortem brain samples often represent
the end stage of the disease and therefore
offer few if any clues regarding the
etiology and molecular mechanisms
underlying pathogenesis. Mouse models
expressing FAD mutations have contrib-
uted invaluably to our current under-
standing of AD; however, they fail to fully
recapitulate AD pathogenesis in humans
as none exhibit b-amyloid-driven tau
tangle formation. In contrast, genetic
studies indicate that in humans, AD isa b-amyloid-induced tauopathy. Funda-
mental species-specific differences in
genome and protein composition be-
tween mice and humans likely preclude
the recapitulation of bona fide AD patho-
logical events in animal models. While
immortalized cell lines and primary rodent
cell cultures have been useful for eluci-
dating the molecular mechanism of AD
pathogenesis, they do not adequately
represent the environmental features of
native neurons.
A previous study has shown that human
fibroblasts can be reprogrammed, by
transient expression of a small number
of genes, into induced pluripotent stem
cells (iPSCs) that functionally and pheno-
typically resemble embryonic stem cells
(Takahashi and Yamanaka, 2006). Two
recent studies, Yagi et al. (2011) and Israel
et al. (2012), provide proof of principle that
iPSCs can be used to model patient-
specific AD pathology in vitro, recapitu-
lating several pathological features of
AD. Yagi et al. (2011) generated iPSCs
from fibroblasts of FAD patients carrying
mutations in PSEN1 (A246E; Sherrington
et al., 1995) or PSEN2 (N141l; Levy-Lahad
et al., 1995). Neurons differentiated from
these iPSCs displayed elevated ratios
of Ab42 to Ab40, a hallmark feature of
FAD with presenilin or APP mutations
(reviewed in Tanzi and Bertram, 2005).
Israel et al. (2012) generated iPSC lines
from six individuals, including two sAD
patients (sAD1/sAD2), two FAD patients
(harboring a duplication of APP; APPDp),
and two age-matched nondemented
controls. Virtually all iPSC lines were
shown to differentiate into neurons that
form functional synaptic contacts, exhibit
normal electrophysiological activity, and
express GABAergic and glutamatergic
neuronal markers. The iPSC-derived
neurons from the APPDp patients and theCell Stem CellsAD2 patient exhibited significantly higher
levels of secreted Ab40 relative to control
neurons, whereas the sAD1 iPSC-derived
neurons did not.
Unfortunately, the authors were not
able to provide data regarding the ratio
of Ab42 to Ab40, as Ab42 secretion was
below the detection sensitivity of their
system. The Ab42/Ab40 ratio is of partic-
ular relevance, since Ab42 is considered
the toxic aggregate-prone species and
is the main component of b-amyloid
plaques in AD. However, it should be
noted that the number of neurons for
each assay was relatively small and in
most cases, the neurons generated may
not have been fully mature. As such,
future studies will need to measure
Ab42/Ab40 ratios during extended culture
periods, and preferably with larger
numbers of neurons.
Although both APPDp and sAD2
neurons were also shown to have signifi-
cantly higher levels of phospho-Tau
(p-Tau), abnormal tau protein accumula-
tion or tangle formation was not observed.
In future studies, it will be crucial to assess
whether sAD and/or FAD iPSC-derived
neurons can be induced to form actual
neurofibrillary tangles, and whether treat-
ments of iPSC-derived neurons with
exogenous Ab affect the biochemical
dynamics of tau proteins. Interestingly,
APPDp and sAD2 neurons also had
increased levels of active glycogen syn-
thase kinase-3b (GSK-3b), a kinase that
phosphorylates tau. Despite these cellular
changes in Ab, tau, and GSK-3b, iPSC-
derived neurons from AD patients did
not display synaptic loss, a feature corre-
lated with the severity of dementia in AD.
Whether this lack of synaptic pathology
may be due to the limited culture duration
is unclear, and will need to be further
investigated.10, March 2, 2012 ª2012 Elsevier Inc. 235
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PreviewsPerhaps one of the most interesting
findings in the Israel et al. (2012) study
was that treatment with b-secretase
inhibitors, but not g-secretase inhibitors,
reduced levels of p-Tau and active
GSK-3b. This would argue that b-secre-
tase-derived products of APP besides
Abmay affect downstream tau pathology.
However, caution would be advised
before firmly drawing such a conclusion
because g-secretase inhibitors can
adversely affect neuronal differentiation
and, perhaps, exert their own neurotox-
icity, leading to tauopathy. Nonetheless,
if this intriguing result were confirmed, it
could challenge the amyloid cascade
hypothesis that posits that Ab is the sole
initiator of tauopathy.
Collectively, Israel and colleagues have
shown that iPSC technology can be used
to observe phenotypes of AD patients, not
only for FAD (Qiang et al., 2011; Yagi et al.,
2011), but also for sAD cases. However, it
is important to note that only one of the
two sAD cell lines recapitulated the APPDp
Ab phenotype. Nonetheless, the ob-
served phenotypic similarity between
APPDp and at least one sAD patient
suggests that the mechanism underlying
autosomal-dominant forms of FAD may
be relevant to the pathogenesis of sAD.
Clearly, larger numbers of samples will
be needed to more comprehensively
investigate the phenotypic heterogeneity
of sAD in future studies. Finally, tau-
related changes were observed concom-
itant with the Ab phenotype, indicating236 Cell Stem Cell 10, March 2, 2012 ª2012that human iPSC-derived neurons
could prove particularly useful for more
effectively assessing the functional rela-
tionship between Ab and tau in AD
pathogenesis.
Since the discovery of iPSCs, scientists
have been excited by the potential of
these cells for modeling diseases,
screening drugs, and even being an
option in cell replacement therapy.
However, there remain numerous open
questions regarding iPSC technology,
including which cell lines serve as the
best controls for AD-iPSCs. Are iPSCs
from age/gender-matched healthy indi-
viduals or family members regardless of
age/gender, or patient-derived iPSCs in
which ADmutations have been converted
to wild-type, the most appropriate?
It is also fair to question whether a cell
culture that contains only one or two cell
types successfully represents AD, which
is a complex disease involving both
neuronal and glial activity. As such, future
studies should be aimed at investigating
cell-autonomous and non-cell-autono-
mous effects in a more diverse set of
differentiated cell types generated from
iPSCs. Particularly because nonneuronal
cells are involved in Ab clearance and
inflammation, iPSC-derived glia from AD
patients may be differentially affected.
Finally, it is not clear whether genetically
engineered iPSC-derived neurons are
true representatives of primary human
neurons because they exhibit gene
expression patterns more similar toElsevier Inc.human fetal brain tissue (Israel et al.,
2012), whereas AD affects the adult
elderly brain. Despite these challenges,
iPSC technology provides an innovative
strategy for the study of AD and should
greatly facilitate efforts to develop thera-
pies for the treatment and prevention of
this devastating disorder.
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